靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.
100 项与 Avana Health, Inc. 相关的临床结果
0 项与 Avana Health, Inc. 相关的专利(医药)
100 项与 Avana Health, Inc. 相关的药物交易
100 项与 Avana Health, Inc. 相关的转化医学